Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug Therapy01:28

Drug Therapy

446
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
446
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Therapies02:49

Cancer Therapies

8.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.

Crohn's & colitis 360·2026
Same author

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Inflammatory bowel diseases·2026
Same author

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Inflammatory bowel diseases·2026
Same author

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.

Advances in therapy·2026
Same author

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

BMJ open·2025
Same author

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Contemporary clinical trials communications·2025

Related Experiment Video

Updated: Apr 28, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Can we get more from our current treatments?

Peter M Irving1

  • 1Department of Gastroenterology, Guy's and St. Thomas' NHS Foundation Trust, Diabetes and Nutritional Sciences Division, King's College London, London, UK.

Best Practice & Research. Clinical Gastroenterology
|June 11, 2014
PubMed
Summary

Optimizing drug therapy is crucial for managing Crohn's disease, a chronic condition requiring lifelong treatment. This review focuses on maximizing the effectiveness of commonly used medications for Crohn's disease patients.

Keywords:
Anti-TNFAnti-TNF drug levelsAnti-drug antibodiesAzathioprine metabolitesCorticosteroidsCrohn's diseaseMethotrexateOptimising therapyThiopurine methyl transferaseThiopurines

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Experiment Videos

Last Updated: Apr 28, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Area of Science:

  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Crohn's disease is a chronic, incurable inflammatory bowel disease necessitating long-term management.
  • Anti-tumor necrosis factor (anti-TNF) agents have significantly improved Crohn's disease treatment but are limited by immunogenicity and loss of response.
  • Limited therapeutic options exist, including immunomodulators like methotrexate, azathioprine, and mercaptopurine.

Purpose of the Study:

  • To review and discuss the optimization of commonly used drugs in Crohn's disease management.
  • To highlight the importance of maximizing drug efficacy given the limited treatment landscape.
  • To address the needs of patients with active Crohn's disease refractory to standard therapies.

Main Methods:

  • Literature review focusing on drug optimization strategies in Crohn's disease.
  • Analysis of factors contributing to treatment response and loss of response.
  • Discussion of therapeutic approaches for patients with refractory disease.

Main Results:

  • Anti-TNF agents and immunomodulators are key therapies, but their long-term effectiveness can be compromised.
  • Drug optimization is essential to maintain treatment efficacy and avoid premature discontinuation.
  • Strategies for optimizing drug use are critical for patients failing standard treatments.

Conclusions:

  • Effective management of Crohn's disease relies on optimizing the use of available therapies.
  • Maximizing the benefit of anti-TNF agents and immunomodulators is crucial for long-term patient outcomes.
  • Further research and clinical strategies are needed to improve drug utilization in Crohn's disease.